Targeting ferroptosis resistance resensitizes metastatic HR+HER2− breast cancer cells to palbociclib-hormone therapy

Charles Pottier; Laetitia Montero-Ruiz; Robin Jehay; Coline Wery; Dominique Baiwir; Gabriel Mazzucchelli; Sophie Bekisz; Romain Thissen; Claire Josse; Andrée Rorive; Stéphanie Gofflot; Ahmed Dahmani; Ludivine Morisset; Joëlle Collignon; Philipe Delvenne; Elisabetta Marangoni; Agnès Noël; Guy Jerusalem; Nor Eddine Sounni

doi:10.1002/cac2.12646

Cancer Communications ›› 2025, Vol. 45 ›› Issue (4) : 456 -459. DOI: 10.1002/cac2.12646

LETTER TO THE JOURNAL

Targeting ferroptosis resistance resensitizes metastatic HR⁺HER2⁻ breast cancer cells to palbociclib-hormone therapy

Author information +

¹. Cancer Metabolism and Tumor Microenvironment Group, Interdisciplinary Group for Applied Genoproteomics (GIGA), University of Liège, Liège, Belgium

². Medical Oncology Department, University Hospital of Liège, Liège, Belgium

³. Laboratory of Tumor and Development Biology, Interdisciplinary Group for Applied Genoproteomics (GIGA) Appliquée, University of Liège, Liège, Belgium

⁴. Proteomics Facility, Interdisciplinary Group for Applied Genoproteomics (GIGA), University of Liège, Liège, Belgium

⁵. Biomechanics Research Unit, In silico Medicine, Interdisciplinary Group for Applied Genoproteomics (GIGA), University of Liège, Liège, Belgium

⁶. Human Genetics Department, Interdisciplinary Group for Applied Genoproteomics (GIGA), University of Liège, Liège, Belgium

⁷. Biobank of the University Hospital of Liège, University of Liège, Liège, Belgium

⁸. Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, Paris, France

⁹. Anatomie et cytologie pathologiques, University Hospital of Liège, Liège, Belgium

nesounni@uliege.be

Show less

History +

PDF

Cite this article

Download citation ▾

Charles Pottier, Laetitia Montero-Ruiz, Robin Jehay, Coline Wery, Dominique Baiwir, Gabriel Mazzucchelli, Sophie Bekisz, Romain Thissen, Claire Josse, Andrée Rorive, Stéphanie Gofflot, Ahmed Dahmani, Ludivine Morisset, Joëlle Collignon, Philipe Delvenne, Elisabetta Marangoni, Agnès Noël, Guy Jerusalem, Nor Eddine Sounni. Targeting ferroptosis resistance resensitizes metastatic HR⁺HER2⁻ breast cancer cells to palbociclib-hormone therapy. Cancer Communications, 2025, 45(4): 456-459 DOI:10.1002/cac2.12646

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016; 17(4): 425–439.

[2]	O'leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discov. 2018; 8(11): 1390–1403

[3]	Asghar US, Kanani R, Roylance R, Mittnacht S. Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. JCO Precis Oncol. 2022; 6(6): e2100002.

[4]	Cadenas C, Vosbeck S, Edlund K, Grgas K, Madjar K, Hellwig B, et al. LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer. Int J Cancer. 2019; 145(4): 901–915.

[5]	Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E, et al. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021; 43: 102006.

[6]	Aiken CT, Kaake RM, Wang X, Huang L. Oxidative Stress-Mediated Regulation of Proteasome Complexes. Mol Cell Proteomics. 2011; 10(5): R110.

[7]	Fujihara KM, Zhang BZ, Jackson TD, Ogunkola MO, Nijagal B, Milne JV, et al. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. Sci Adv [Internet]. 2022; 8(37): eabm9427.

[8]	Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021; 39(14): 1584–1594.

[9]	Randolph JT, O'Connor MJ, Han F, Hutchins CW, Siu YA, Cho M, et al. Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis In Vivo. J Med Chem. 2023; 66(6): 3852–3865.

[10]	El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat Commun. 2023; 14(1): 4221.